Research programme: antibody therapeutics - Diversa/MerckAlternative Names: Antibody therapeutics research programme - Diversa/Merck
Latest Information Update: 19 Mar 2010
At a glance
- Originator Diversa; Merck & Co
- Class Antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 04 Mar 2008 This programme is still in active development
- 14 Jan 2005 Preclinical trials in Undefined in USA (Parenteral)